Scarica l'app Stockscreener
36.85
0.12%
0.045
Dopo l'orario di chiusura:
36.81
-0.04
-0.11%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BBIO Giù?
Forum
Previsione
Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie
10 Best Performing Pharma Stocks So Far in 2025 - Insider Monkey
BridgeBio price target raised to $52 from $49 at Scotiabank - Yahoo Finance
BridgeBio Pharma Q4 2024 Earnings: Revenue Surpasses Estimates a - GuruFocus.com
BridgeBio: Strong Commercial Momentum for Attruby Sets the Stage for Long-Term Profitability - Morningstar
BridgeBio’s Attruby Off To A Strong Start – But Alnylam Awaits - News & Insights
BridgeBio Pharma Reports Strong 2024 Financial Results - TipRanks
BridgeBio Pharma, Inc. SEC 10-K Report - TradingView
BridgeBio: Strong Start For Attruby (NASDAQ:BBIO) - Seeking Alpha
BridgeBio’s stock rises on promising sales of recently approved heart drug - MM+M Online
BridgeBio’s heart drug launch gets off to a fast start - BioPharma Dive
BridgeBio Pharma stock hits 52-week high at $39.23 - Investing.com
Risky weight loss, grad school acceptance cuts, and more major biotech news of the day - STAT
BridgeBio Pharma Inc (BBIO) Q4 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
BridgeBio Pharma (BBIO) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
BridgeBio Pharma earnings missed by $0.27, revenue topped estimates - Investing.com
BridgeBio Pharma Q4 Loss Widens, Revenue Rises -- Shares Up Pre-Bell -February 20, 2025 at 08:04 am EST - Marketscreener.com
BRIDGEBIO PHARMA Earnings Results: $BBIO Reports Quarterly Earnings - Nasdaq
BridgeBio Pharma: Q4 Earnings Snapshot - The Bakersfield Californian
Earnings Flash (BBIO) BridgeBio Pharma Posts Q4 Revenue $5.9M, vs. FactSet Est of $3.1M - Marketscreener.com
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update - TradingView
BridgeBio Pharma CFO Brian Stephenson sells $149,973 in stock By Investing.com - Investing.com Nigeria
BridgeBio Pharma CEO Neil Kumar sells $1.14 million in stock By Investing.com - Investing.com Nigeria
BridgeBio Pharma CEO Neil Kumar sells $1.14 million in stock - Investing.com India
BridgeBio Pharma CFO Brian Stephenson sells $149,973 in stock - Investing.com India
Earnings Flash (BBIO) BridgeBio Pharma Posts Q4 Net Loss $-1.40 a Share, vs. FactSet Est of $-1.13 Loss - Marketscreener.com
Market Whales and Their Recent Bets on BBIO Options - Benzinga
Why Is BridgeBio Pharma Stock Trading Higher On Friday? - MSN
Piper Sandler maintains $46 target on BridgeBio stock after survey - Investing.com India
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 7.2%What's Next? - MarketBeat
Scotiabank Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock - MarketBeat
(BBIO) Trading Signals - Stock Traders Daily
Harvey Capital Management Inc. Takes $354,000 Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
HC Wainwright Reaffirms Buy Rating for BridgeBio Pharma (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma to Report Fourth Quarter and Full Year - GlobeNewswire
BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025 - The Manila Times
BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February - EIN News
BridgeBio price target raised to $49 from $48 at Scotiabank - Yahoo Finance
BridgeBio Pharma’s European Approval of Acoramidis and Strong Pipeline Justifies Buy Rating - TipRanks
BridgeBio’s receives EU approval for its Transthyretin Amyloidosis treatment - MSN
BridgeBio shares rise on Scotiabank price target boost - MSN
EC grants marketing authorisation to BridgeBio’s ATTR-CM treatment - MSN
BridgeBio shares rise on Scotiabank price target boost By Investing.com - Investing.com South Africa
BridgeBio gets EU nod for ATTR cardiomyopathy drug - pharmaphorum
BridgeBio Pharma Announces EU Approval Of BEYONTTRA For Treatment Of ATTR-CM - Nasdaq
BridgeBio wins EU approval for Beyonttra for ATTR-CM - The Pharma Letter
Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK - BioPharma Dive
BridgeBio Pharma Says Beyonttra Gets EU Marketing Approval for Transthyretin Amyloidosis - Marketscreener.com
BridgeBio announces EC marketing authorization for BETONTTRA - TipRanks
BEYONTTRA™ (acoramidis), the First Near Complete TTR - GlobeNewswire
BBIO Secures Major EU Win: Revolutionary Heart Drug Shows 42% Mortality Reduction - StockTitan
BridgeBio's Heart Disease Drug Meets Late-stage End Points - BW Healthcare World
Why BridgeBio Pharma, Inc. (BBIO) Is Among the Best Healthcare Stocks To Buy According to Analysts - Insider Monkey
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Down 5.5% Following Insider Selling - MarketBeat
BridgeBio: Post Attruby Approval, Shares Don't Look Such Good ValueRating Downgrade - Seeking Alpha
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):